EGFR and non-small cell lung carcinoma: EGFR M+ NSCLC cells (HCC-827, PC-9) were markedly more sensitive to growth inhibition by an EGFR TKI (gefitinib) as well as the AKT inhibitor MK2206, compared with EGFR wild-type cells (A549) and EGFR T790M cells (H1975) (Table 1).